Prognostic value of CD73 expression in resected colorectal cancer liver metastasis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–8. doi:10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, Buttard B, Morgand E, Bruni D, Jouret-Mourin A, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175(3):751–765 e716. doi:10.1016/j.cell.2018.09.018.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst. 2018;110:97–108.
   Google Scholar
• Turcotte S, Katz SC, Shia J, Jarnagin WR, Kingham TP, Allen PJ, Fong Y, D’Angelica MI, DeMatteo RP. Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases. Cancer Immunol Res. 2014;2(6):530–537. doi:10.1158/2326-6066.CIR-13-0180.
   PubMed Web of Science ®Google Scholar
• Turcotte S, Gros A, Tran E, Lee CCR, Wunderlich JR, Robbins PF, Rosenberg SA. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. 2014;20(2):331–343. doi:10.1158/1078-0432.CCR-13-1736.
   PubMed Web of Science ®Google Scholar
• Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–1390. doi:10.1126/science.aad1253.
   PubMed Web of Science ®Google Scholar
• Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:709–724. doi:10.1038/nrc.2017.86.
   PubMed Web of Science ®Google Scholar
• Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J. Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett. 2019;205:31–39. doi:10.1016/j.imlet.2018.05.001.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang Y, Lin X, Gao Y, Zhu Y. Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review. Oncotarget. 2017;8:57327–57336. doi:10.18632/oncotarget.16905.
   PubMedGoogle Scholar
• Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19:355–367. doi:10.1016/j.molmed.2013.03.005.
   PubMed Web of Science ®Google Scholar
• Stagg J, Beavis PA, Divisekera U, Liu MCP, Moller A, Darcy PK, Smyth MJ. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012;72(9):2190–2196. doi:10.1158/0008-5472.CAN-12-0420.
   PubMed Web of Science ®Google Scholar
• Stagg J. The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology. 2012;1:217–218. doi:10.4161/onci.1.2.18101.
   PubMed Web of Science ®Google Scholar
• Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D, Grimaldi AM, Pinto A, Ascierto PA. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med. 2017;15:244. doi:10.1186/s12967-017-1348-8.
   PubMed Web of Science ®Google Scholar
• Wu X-R, He X-S, Chen Y-F, Yuan R-X, Zeng Y, Lian L, Zou Y-F, Lan N, Wu X-J, Lan P, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106(2):130–137. doi:10.1002/jso.v106.2.
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304. doi:10.1093/annonc/mdl386.
   PubMed Web of Science ®Google Scholar
• Grosset AA, Loayza-Vega K, Adam-Granger E, Birlea M, Gilks B, Nguyen B, Soucy G, Tran-Thanh D, Albadine R, Trudel D. Hematoxylin and Eosin counterstaining protocol for immunohistochemistry interpretation and diagnosis. Appl Immunohistochem Mol Morphol. 2017;27(7):558–563. doi: 10.1097/PAI.0000000000000626.
   Google Scholar
• Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol. 2018;29(4):1056–1062. doi:10.1093/annonc/mdx730.
   PubMed Web of Science ®Google Scholar
• Gaudreau PO, Allard B, Turcotte M, Stagg J. CD73-adenosine reduces immune responses and survival in ovarian cancer patients. Oncoimmunology. 2016;5:e1127496. doi:10.1080/2162402X.2015.1127496.
   PubMed Web of Science ®Google Scholar
• Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J. CD73 expression is an independent prognostic factor in prostate cancer. Clin Cancer Res. 2016;22(1):158–166. doi:10.1158/1078-0432.CCR-15-1181.
   PubMed Web of Science ®Google Scholar
• Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, et al. CD73 promotes resistance to HER2/ErbB2 antibody therapy. Cancer Res. 2017;77(20):5652–5663. doi:10.1158/0008-5472.CAN-17-0707.
   PubMed Web of Science ®Google Scholar
• Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–130. doi:10.1111/his.2007.50.issue-1.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–7259. doi:10.1158/1078-0432.CCR-04-0713.
   PubMed Web of Science ®Google Scholar
• Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29:5346–5358. doi:10.1038/onc.2010.292.
   PubMed Web of Science ®Google Scholar
• Eroglu A, Canbolat O, Demirci S, Kocaoĝlu H, Eryavuz Y, Akgül H. Activities of adenosine deaminase and 5ʹ-nucleotidase in cancerous and noncancerous human colorectal tissues. Med Oncol. 2000;17:319–324. doi:10.1007/BF02782198.
   PubMed Web of Science ®Google Scholar
• Zhang B, Song B, Wang X, Chang X-S, Pang T, Zhang X, Yin K, Fang G-E. The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma. Tumour Biol. 2015;36(7):5459–5466. doi:10.1007/s13277-015-3212-x.
   PubMedGoogle Scholar
• Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol. 2009;183(9):5487–5493. doi:10.4049/jimmunol.0901247.
   PubMed Web of Science ®Google Scholar
• Zarek PE, Huang C-T, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008;111(1):251–259. doi:10.1182/blood-2007-03-081646.
   PubMed Web of Science ®Google Scholar
• Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7:759–770. doi:10.1038/nrd2638.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar
• Heuts DP, Weissenborn MJ, Olkhov RV, Shaw AM, Gummadova J, Levy C, Scrutton NS. Crystal structure of a soluble form of human CD73 with ecto-5ʹ-nucleotidase activity. Chembiochem. 2012;13:2384–2391. doi:10.1002/cbic.201200426.
   PubMed Web of Science ®Google Scholar
• Vaara ST, Hollmen M, Korhonen A-M, Maksimow M, Ala-Kokko T, Salmi M, Jalkanen S, Pettilä V. Soluble CD73 in Critically Ill septic patients - data from the prospective FINNAKI study. PLoS One. 2016;11(10):e0164420. doi:10.1371/journal.pone.0164420.
   PubMed Web of Science ®Google Scholar
• Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta. 2008;1783:673–694. doi:10.1016/j.bbamcr.2008.01.024.
   PubMed Web of Science ®Google Scholar